标题
Targeting micro-environmental pathways by PROTACs as a therapeutic strategy
作者
关键词
-
出版物
SEMINARS IN CANCER BIOLOGY
Volume -, Issue -, Pages -
出版商
Elsevier BV
发表日期
2022-07-04
DOI
10.1016/j.semcancer.2022.07.001
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Discovery of Potent, Selective, and In Vivo Efficacious AKT Kinase Protein Degraders via Structure–Activity Relationship Studies
- (2022) Xufen Yu et al. JOURNAL OF MEDICINAL CHEMISTRY
- Targeting the NOTCH1-MYC-CD44 axis in leukemia-initiating cells in T-ALL
- (2022) Sujan Piya et al. LEUKEMIA
- Development of Potent and Selective Janus Kinase 2/3 Directing PG–PROTACs
- (2022) Lisa J. Alcock et al. ACS Medicinal Chemistry Letters
- Discovery of novel potent covalent inhibitor-based EGFR degrader with excellent in vivo efficacy
- (2022) Shi Shi et al. BIOORGANIC CHEMISTRY
- EZH2 noncanonically binds cMyc and p300 through a cryptic transactivation domain to mediate gene activation and promote oncogenesis
- (2022) Jun Wang et al. NATURE CELL BIOLOGY
- Characterization of INCB086550: A Potent and Novel Small-Molecule PD-L1 Inhibitor
- (2022) Holly K. Koblish et al. Cancer Discovery
- Development of Antibody-Based PROTACs for the Degradation of the Cell-Surface Immune Checkpoint Protein PD-L1
- (2021) Adam D. Cotton et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Structure-Based Discovery of SIAIS001 as an Oral Bioavailability ALK Degrader Constructed from Alectinib
- (2021) Chaowei Ren et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of a PROTAC targeting ALK with in vivo activity
- (2021) Guoyi Yan et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Design and Synthesis of EZH2-Based PROTACs to Degrade the PRC2 Complex for Targeting the Noncatalytic Activity of EZH2
- (2021) Zhihao Liu et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of a first-in-class CDK2 selective degrader for AML differentiation therapy
- (2021) Liguo Wang et al. Nature Chemical Biology
- Comparative evaluation of cardiovascular risks among nine FDA-approved VEGFR-TKIs in patients with solid tumors: a Bayesian network analysis of randomized controlled trials
- (2021) Wanting Hou et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Bispecific Estrogen Receptor α Degraders Incorporating Novel Binders Identified Using DNA-Encoded Chemical Library Screening
- (2021) Jeremy S. Disch et al. JOURNAL OF MEDICINAL CHEMISTRY
- Cancer Selective Target Degradation by Folate-Caged PROTACs
- (2021) Jing Liu et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Vadadustat in Patients with Anemia and Non–Dialysis-Dependent CKD
- (2021) Glenn M. Chertow et al. NEW ENGLAND JOURNAL OF MEDICINE
- SD-91 as A Potent and Selective STAT3 Degrader Capable of Achieving Complete and Long-Lasting Tumor Regression
- (2021) Haibin Zhou et al. ACS Medicinal Chemistry Letters
- Arginine methyltransferase PRMT5 negatively regulates cGAS-mediated antiviral immune response
- (2021) Dapeng Ma et al. Science Advances
- In vitro and in vivo degradation of programmed cell death ligand 1 (PD-L1) by a proteolysis targeting chimera (PROTAC)
- (2021) Yubo Wang et al. BIOORGANIC CHEMISTRY
- Degradation of Janus kinases in CRLF2-rearranged acute lymphoblastic leukemia
- (2021) Yunchao Chang et al. BLOOD
- Folate-Guided Protein Degradation by Immunomodulatory Imide Drug-Based Molecular Glues and Proteolysis Targeting Chimeras
- (2021) He Chen et al. JOURNAL OF MEDICINAL CHEMISTRY
- TF-PROTACs Enable Targeted Degradation of Transcription Factors
- (2021) Jing Liu et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- AKT degradation selectively inhibits the growth of PI3K/PTEN pathway mutant cancers with wild-type KRAS and BRAF by destabilizing Aurora kinase B
- (2021) Jia Xu et al. Cancer Discovery
- Aspects of the Tumor Microenvironment Involved in Immune Resistance and Drug Resistance
- (2021) Khalil Khalaf et al. Frontiers in Immunology
- Design, Synthesis, and Evaluation of Potent, Selective, and Bioavailable AKT Kinase Degraders
- (2021) Xufen Yu et al. JOURNAL OF MEDICINAL CHEMISTRY
- Daprodustat for the Treatment of Anemia in Patients Undergoing Dialysis
- (2021) Ajay K. Singh et al. NEW ENGLAND JOURNAL OF MEDICINE
- Hi-JAK-ing the ubiquitin system: The design and physicochemical optimisation of JAK PROTACs
- (2020) Rishi R. Shah et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Selective inhibition of Ph-positive ALL cell growth through kinase-dependent and independent effects by CDK6-specific PROTACs
- (2020) Marco De Dominici et al. BLOOD
- Single-Cell Transcriptome Atlas of Murine Endothelial Cells
- (2020) Joanna Kalucka et al. CELL
- Development of a Brigatinib degrader (SIAIS117) as a potential treatment for ALK positive cancer resistance
- (2020) Ning Sun et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of potent epidermal growth factor receptor (EGFR) degraders by proteolysis targeting chimera (PROTAC)
- (2020) Hao Zhang et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of Potent and Selective Epidermal Growth Factor Receptor (EGFR) Bifunctional Small-Molecule Degraders
- (2020) Meng Cheng et al. JOURNAL OF MEDICINAL CHEMISTRY
- FDA approves an inhibitor of a novel ‘epigenetic writer’
- (2020) Asher Mullard NATURE REVIEWS DRUG DISCOVERY
- PROTACs: A novel strategy for cancer therapy
- (2020) Jing Liu et al. SEMINARS IN CANCER BIOLOGY
- Light-induced control of protein destruction by opto-PROTAC
- (2020) Jing Liu et al. Science Advances
- Selective CDK6 degradation mediated by cereblon, VHL, and novel IAP-recruiting PROTACs
- (2020) Niall A. Anderson et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- CD133 inhibition via autophagic degradation in pemetrexed-resistant lung cancer cells by GMI, a fungal immunomodulatory protein from Ganoderma microsporum
- (2020) I-Lun Hsin et al. BRITISH JOURNAL OF CANCER
- The future of cancer immunotherapy: microenvironment-targeting combinations
- (2020) Yonina R. Murciano-Goroff et al. CELL RESEARCH
- Design and synthesis of selective degraders of EGFRL858R/T790M mutant
- (2020) Xin Zhang et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Efficient Targeted Degradation via Reversible and Irreversible Covalent PROTACs
- (2020) Ronen Gabizon et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- SOX4 activates CXCL12 in hepatocellular carcinoma cells to modulate endothelial cell migration and angiogenesis in vivo
- (2020) Chi-Neu Tsai et al. ONCOGENE
- p300/CBP inhibition enhances the efficacy of programmed death-ligand 1 blockade treatment in prostate cancer
- (2020) Jinghui Liu et al. ONCOGENE
- Development of Selective Histone Deacetylase 6 (HDAC6) Degraders Recruiting Von Hippel–Lindau (VHL) E3 Ubiquitin Ligase
- (2020) Ka Yang et al. ACS Medicinal Chemistry Letters
- Hydroxamic Acids Immobilized on Resins (HAIRs): A Toolbox for the Synthesis of Dual‐Targeting HDAC Inhibitors and HDAC Degraders (PROTACs)
- (2020) Laura Sinatra et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Discovery and biological evaluation of proteolysis targeting chimeras (PROTACs) as an EGFR degraders based on osimertinib and lenalidomide
- (2020) Kailun He et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Multi-phenotype CRISPR-Cas9 Screen Identifies p38 Kinase as a Target for Adoptive Immunotherapies
- (2020) Devikala Gurusamy et al. CANCER CELL
- Discovery of novel resorcinol diphenyl ether-based PROTAC-like molecules as dual inhibitors and degraders of PD-L1
- (2020) Binbin Cheng et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of First-in-class Protein Arginine Methyltransferase 5 (PRMT5) Degraders
- (2020) Yudao Shen et al. JOURNAL OF MEDICINAL CHEMISTRY
- Global PROTAC Toolbox for Degrading BCR–ABL Overcomes Drug-Resistant Mutants and Adverse Effects
- (2020) Yiqing Yang et al. JOURNAL OF MEDICINAL CHEMISTRY
- Lysosome-targeting chimaeras for degradation of extracellular proteins
- (2020) Steven M. Banik et al. NATURE
- The CDK inhibitor CR8 acts as a molecular glue degrader that depletes cyclin K
- (2020) Mikołaj Słabicki et al. NATURE
- A PROTAC peptide induces durable β-catenin degradation and suppresses Wnt-dependent intestinal cancer
- (2020) Hongwei Liao et al. Cell Discovery
- Optimal linker length for small molecule PROTACs that selectively target p38α and p38β for degradation
- (2020) Craig Donoghue et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Discovery and development of selective aldehyde dehydrogenase 1A1 (ALDH1A1) inhibitors
- (2020) Bingyan Li et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- First orally bioavailable prodrug of proteolysis targeting chimera (PROTAC) degrades cyclin-dependent kinases 2/4/6 in vivo
- (2020) Mingming Wei et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Acetylation-dependent regulation of PD-L1 nuclear translocation dictates the efficacy of anti-PD-1 immunotherapy
- (2020) Yang Gao et al. NATURE CELL BIOLOGY
- PROTAC-DB: an online database of PROTACs
- (2020) Gaoqi Weng et al. NUCLEIC ACIDS RESEARCH
- Simultaneous Inhibition of SIRT2 Deacetylase and Defatty-Acylase Activities via a PROTAC Strategy
- (2020) Jun Young Hong et al. ACS Medicinal Chemistry Letters
- Enhancing intracellular accumulation and target engagement of PROTACs with reversible covalent chemistry
- (2020) Wen-Hao Guo et al. Nature Communications
- Mapping the Degradable Kinome Provides a Resource for Expedited Degrader Development
- (2020) Katherine A. Donovan et al. CELL
- Discovery of potent small molecule PROTACs targeting mutant EGFR
- (2020) Hong-Yi Zhao et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Snapshots and ensembles of BTK and cIAP1 protein degrader ternary complexes
- (2020) James Schiemer et al. Nature Chemical Biology
- Translation control of the immune checkpoint in cancer and its therapeutic targeting
- (2019) Yichen Xu et al. NATURE MEDICINE
- Differential PROTAC substrate specificity dictated by orientation of recruited E3 ligase
- (2019) Blake E. Smith et al. Nature Communications
- Developing potent PROTACs tools for selective degradation of HDAC6 protein
- (2019) Zixuan An et al. Protein & Cell
- A chemical approach for global protein knockdown from mice to non-human primates
- (2019) Xiuyun Sun et al. Cell Discovery
- A Pan-ALDH1A Inhibitor Induces Necroptosis in Ovarian Cancer Stem-like Cells
- (2019) Ilana Chefetz et al. Cell Reports
- HDAC3 inhibition up-regulates PD-L1 expression in B-cell lymphomas and augments the efficacy of anti-PD-L1 therapy
- (2019) Siyu Deng et al. MOLECULAR CANCER THERAPEUTICS
- Met inhibition revokes IFNγ-induction of PD-1 ligands in MET-amplified tumours
- (2019) Valentina Martin et al. BRITISH JOURNAL OF CANCER
- Development of Dual and Selective Degraders of Cyclin-Dependent Kinases 4 and 6
- (2019) Baishan Jiang et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- BETP degradation simultaneously targets acute myelogenous leukemic stem cells and the microenvironment
- (2019) Sujan Piya et al. JOURNAL OF CLINICAL INVESTIGATION
- Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer
- (2019) Fabrice André et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting Tumor-Associated Macrophages in Cancer
- (2019) Paulina Pathria et al. TRENDS IN IMMUNOLOGY
- Targeting BCR-ABL1 in Chronic Myeloid Leukemia by PROTAC-mediated Targeted Protein Degradation
- (2019) George M Burslem et al. CANCER RESEARCH
- Development of Multifunctional Histone Deacetylase 6 Degraders with Potent Antimyeloma Activity
- (2019) Hao Wu et al. JOURNAL OF MEDICINAL CHEMISTRY
- Roxadustat for Anemia in Patients with Kidney Disease Not Receiving Dialysis
- (2019) Nan Chen et al. NEW ENGLAND JOURNAL OF MEDICINE
- PI3K/Akt/mTOR inhibitors in cancer: At the bench and bedside
- (2019) Ali S. Alzahrani SEMINARS IN CANCER BIOLOGY
- Duvelisib for CLL/SLL and Follicular Non-Hodgkin Lymphoma
- (2019) Krish Patel et al. BLOOD
- Potent and Preferential Degradation of CDK6 via Proteolysis Targeting Chimera Degraders
- (2019) Shang Su et al. JOURNAL OF MEDICINAL CHEMISTRY
- Aldehyde Dehydrogenase Inhibitors for Cancer Therapeutics
- (2019) Saketh S. Dinavahi et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- ATTEC: a potential new approach to target proteinopathies
- (2019) Zhaoyang Li et al. Autophagy
- A Potent and Selective Small-Molecule Degrader of STAT3 Achieves Complete Tumor Regression In Vivo
- (2019) Longchuan Bai et al. CANCER CELL
- Small-Molecule MYC Inhibitors Suppress Tumor Growth and Enhance Immunotherapy
- (2019) Huiying Han et al. CANCER CELL
- Discovery of SIAIS178 as an Effective BCR-ABL Degrader by Recruiting Von Hippel–Lindau (VHL) E3 Ubiquitin Ligase
- (2019) Quanju Zhao et al. JOURNAL OF MEDICINAL CHEMISTRY
- Start Selective and Rigidify: The Discovery Path toward a Next Generation of EGFR Tyrosine Kinase Inhibitors
- (2019) Harald Engelhardt et al. JOURNAL OF MEDICINAL CHEMISTRY
- Light-Induced Protein Degradation with Photocaged PROTACs
- (2019) Gang Xue et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- A view on drug resistance in cancer
- (2019) Neil Vasan et al. NATURE
- Design, synthesis and biological evaluation of Proteolysis Targeting Chimeras (PROTACs) as a BTK degraders with improved pharmacokinetic properties
- (2019) Saul Jaime-Figueroa et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Structure-Based Discovery of SD-36 as a Potent, Selective, and Efficacious PROTAC Degrader of STAT3 Protein
- (2019) Haibin Zhou et al. JOURNAL OF MEDICINAL CHEMISTRY
- AUTACs: Cargo-Specific Degraders Using Selective Autophagy
- (2019) Daiki Takahashi et al. MOLECULAR CELL
- Discovery of a first-in-class EZH2 selective degrader
- (2019) Anqi Ma et al. Nature Chemical Biology
- Translation Termination Factor GSPT1 Is a Phenotypically Relevant Off-Target of Heterobifunctional Phthalimide Degraders
- (2018) Mette Ishoey et al. ACS Chemical Biology
- Targeting the C481S Ibrutinib-Resistance Mutation in Bruton’s Tyrosine Kinase Using PROTAC-Mediated Degradation
- (2018) Alexandru D. Buhimschi et al. BIOCHEMISTRY
- Development of the first small molecule histone deacetylase 6 (HDAC6) degraders
- (2018) Ka Yang et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- PROTAC-induced BTK degradation as a novel therapy for mutated BTK C481S induced ibrutinib-resistant B-cell malignancies
- (2018) Yonghui Sun et al. CELL RESEARCH
- MET-oncogenic and JAK2-inactivating alterations are independent factors that affect regulation of PD-L1 expression in lung cancer
- (2018) Maria Saigi et al. CLINICAL CANCER RESEARCH
- Proteolysis Targeting Chimeras (PROTACs) of Anaplastic Lymphoma Kinase (ALK)
- (2018) Chengwei Zhang et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Phthalimide conjugations for the degradation of oncogenic PI3K
- (2018) Wenlu Li et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Phase I Dose-Escalation Trial of PT2385, a First-in-Class Hypoxia-Inducible Factor-2α Antagonist in Patients With Previously Treated Advanced Clear Cell Renal Cell Carcinoma
- (2018) Kevin D. Courtney et al. JOURNAL OF CLINICAL ONCOLOGY
- Chemically Induced Degradation of Anaplastic Lymphoma Kinase (ALK)
- (2018) Chelsea E. Powell et al. JOURNAL OF MEDICINAL CHEMISTRY
- Phase 1/2 Study of the Safety and Tolerability of Nivolumab Plus Crizotinib for the First-Line Treatment of Anaplastic Lymphoma Kinase Translocation — Positive Advanced Non–Small Cell Lung Cancer (CheckMate 370)
- (2018) David R. Spigel et al. Journal of Thoracic Oncology
- Delineating the role of cooperativity in the design of potent PROTACs for BTK
- (2018) Adelajda Zorba et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Is β-Catenin a Druggable Target for Cancer Therapy?
- (2018) Can Cui et al. TRENDS IN BIOCHEMICAL SCIENCES
- Induced protein degradation of anaplastic lymphoma kinase (ALK) by proteolysis targeting chimera (PROTAC)
- (2018) Chung Hyo Kang et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI?
- (2018) Gonzalo Recondo et al. Nature Reviews Clinical Oncology
- Bruton's Tyrosine Kinase degradation as a therapeutic strategy for cancer
- (2018) Dennis Dobrovolsky et al. BLOOD
- MDM2-Recruiting PROTAC Offers Superior, Synergistic Antiproliferative Activity via Simultaneous Degradation of BRD4 and Stabilization of p53
- (2018) John Hines et al. CANCER RESEARCH
- Phosphorylated RB Promotes Cancer Immunity by Inhibiting NF-κB Activation and PD-L1 Expression
- (2018) Xin Jin et al. MOLECULAR CELL
- HIP1R targets PD-L1 to lysosomal degradation to alter T cell–mediated cytotoxicity
- (2018) Huanbin Wang et al. Nature Chemical Biology
- The kinase TBK1 functions in dendritic cells to regulate T cell homeostasis, autoimmunity, and antitumor immunity
- (2017) Yichuan Xiao et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Chemically Induced Degradation of Sirtuin 2 (Sirt2) by a Proteolysis Targeting Chimera (PROTAC) Based on Sirtuin Rearranging Ligands (SirReals)
- (2017) Matthias Schiedel et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of a Small-Molecule Degrader of Bromodomain and Extra-Terminal (BET) Proteins with Picomolar Cellular Potencies and Capable of Achieving Tumor Regression
- (2017) Bing Zhou et al. JOURNAL OF MEDICINAL CHEMISTRY
- BET Bromodomain Proteins Function as Master Transcription Elongation Factors Independent of CDK9 Recruitment
- (2017) Georg E. Winter et al. MOLECULAR CELL
- CDK4/6 inhibition triggers anti-tumour immunity
- (2017) Shom Goel et al. NATURE
- Cyclin D–CDK4 kinase destabilizes PD-L1 via cullin 3–SPOP to control cancer immune surveillance
- (2017) Jinfang Zhang et al. NATURE
- Cancer stem cells revisited
- (2017) Eduard Batlle et al. NATURE MEDICINE
- Anticancer sulfonamides target splicing by inducing RBM39 degradation via recruitment to DCAF15
- (2017) Ting Han et al. SCIENCE
- The challenge of targeting cancer stem cells to halt metastasis
- (2017) Alice Agliano et al. SEMINARS IN CANCER BIOLOGY
- Targeting the Allosteric Site of Oncoprotein BCR-ABL as an Alternative Strategy for Effective Target Protein Degradation
- (2017) Kenichiro Shimokawa et al. ACS Medicinal Chemistry Letters
- CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation
- (2017) Jiehui Deng et al. Cancer Discovery
- Targeting ALK: Precision Medicine Takes on Drug Resistance
- (2017) Jessica J. Lin et al. Cancer Discovery
- Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids
- (2017) Russell W. Jenkins et al. Cancer Discovery
- Small-molecule inhibitors of PD-1/PD-L1 immune checkpoint alleviate the PD-L1-induced exhaustion of T-cells
- (2017) Lukasz Skalniak et al. Oncotarget
- Peptide Blocking of PD-1/PD-L1 Interaction for Cancer Immunotherapy
- (2017) Chunlin Li et al. Cancer Immunology Research
- Development of BCR-ABL degradation inducers via the conjugation of an imatinib derivative and a cIAP1 ligand
- (2016) Yosuke Demizu et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Myeloid-Derived Suppressor Cells Express Bruton's Tyrosine Kinase and Can Be Depleted in Tumor-Bearing Hosts by Ibrutinib Treatment
- (2016) Andrew Stiff et al. CANCER RESEARCH
- The hepatocyte growth factor antagonist NK4 inhibits indoleamine-2,3-dioxygenase expression via the c-Met-phosphatidylinositol 3-kinase-AKT signaling pathway
- (2016) DONGDONG WANG et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Review on EGFR Inhibitors: Critical Updates
- (2016) Davinder Singh et al. MINI-REVIEWS IN MEDICINAL CHEMISTRY
- Treating cancer with selective CDK4/6 inhibitors
- (2016) Ben O'Leary et al. Nature Reviews Clinical Oncology
- PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer
- (2016) Kanak Raina et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- MYC regulates the antitumor immune response through CD47 and PD-L1
- (2016) S. C. Casey et al. SCIENCE
- Aldehyde dehydrogenases inhibition eradicates leukemia stem cells while sparing normal progenitors
- (2016) G Venton et al. Blood Cancer Journal
- BET Bromodomain Inhibition Promotes Anti-tumor Immunity by Suppressing PD-L1 Expression
- (2016) Hengrui Zhu et al. Cell Reports
- Selective Small Molecule Induced Degradation of the BET Bromodomain Protein BRD4
- (2015) Michael Zengerle et al. ACS Chemical Biology
- Blocking of the PD-1/PD-L1 Interaction by aD-Peptide Antagonist for Cancer Immunotherapy
- (2015) Hao-Nan Chang et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Modular PROTAC Design for the Degradation of Oncogenic BCR-ABL
- (2015) Ashton C. Lai et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK
- (2015) Idit Sagiv-Barfi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Phthalimide conjugation as a strategy for in vivo target protein degradation
- (2015) G. E. Winter et al. SCIENCE
- Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway
- (2015) Kim C. Ohaegbulam et al. TRENDS IN MOLECULAR MEDICINE
- Bruton Tyrosine Kinase-Dependent Immune Cell Cross-talk Drives Pancreas Cancer
- (2015) A. J. Gunderson et al. Cancer Discovery
- HDAC Inhibition Upregulates PD-1 Ligands in Melanoma and Augments Immunotherapy with PD-1 Blockade
- (2015) D. M. Woods et al. Cancer Immunology Research
- Idelalisib — A PI3Kδ Inhibitor for B-Cell Cancers
- (2014) David A. Fruman et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Kinase-Independent Function of CDK6 Links the Cell Cycle to Tumor Angiogenesis
- (2013) Karoline Kollmann et al. CANCER CELL
- Inhibition of p300 impairs Foxp3+ T regulatory cell function and promotes antitumor immunity
- (2013) Yujie Liu et al. NATURE MEDICINE
- JAKs and STATs in Immunity, Immunodeficiency, and Cancer
- (2013) John J. O'Shea et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells
- (2013) J. Kronke et al. SCIENCE
- The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
- (2013) G. Lu et al. SCIENCE
- BAY 87-2243, a highly potent and selective inhibitor of hypoxia-induced gene activation has antitumor activities by inhibition of mitochondrial complex I
- (2013) Peter Ellinghaus et al. Cancer Medicine
- Treating ALK-positive lung cancer—early successes and future challenges
- (2012) D. Ross Camidge et al. Nature Reviews Clinical Oncology
- Design, synthesis and biological evaluation of nuclear receptor-degradation inducers
- (2011) Yukihiro Itoh et al. BIOORGANIC & MEDICINAL CHEMISTRY
- The cancer stem cell: premises, promises and challenges
- (2011) Hans Clevers NATURE MEDICINE
- Protein Knockdown Using Methyl Bestatin−Ligand Hybrid Molecules: Design and Synthesis of Inducers of Ubiquitination-Mediated Degradation of Cellular Retinoic Acid-Binding Proteins
- (2010) Yukihiro Itoh et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Identification of a Primary Target of Thalidomide Teratogenicity
- (2010) T. Ito et al. SCIENCE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More